The death-promoting activity of p53 can be inhibited by distinct signaling pathways

Blood

Volumn 100, Issue 12, 2002, Pages 3990-4000

  Lin, Yunping ^a,b   Brown, Lauren ^a,b   Hedley, David W ^a,b   Barber, Dwayne L ^a,b   Benchimol, Samuel ^a,b  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; CYTOCHROME C; CYTOKINE; ERYTHROPOIETIN; GLYCOPROTEIN GP 55; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P53; STAT5 PROTEIN; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ALLELE; ANIMAL CELL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; CELL CYCLE G1 PHASE; CELL DEATH; CELL SURVIVAL; CYTOSOL; ENZYME ACTIVATION; ERYTHROLEUKEMIA CELL; FRIEND LEUKEMIA VIRUS; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; VIRUS CELL TRANSFORMATION;

EID: 0036892576     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-02-0504     Document Type: Article

References (65)

1. Levine AJ. p53, the cellular gatekeeper for growth and division, Cell. 1997;88:323-331.
2. Symonds HL, Krall L, Remington M, et al. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell. 1994;78:703-711.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100:57-70.
4. Wojchowski DM, Gregory RC, Miller CP, Pandit A, Pircher TJ. Signal transduction in the erythropoietin receptor system. Exp Cell Res. 1999;253: 143-156.
5. Kelley LL, Koury MJ, Bondurant MC, Koury ST, Sawyer ST, Wickrema A. Survival or death of individual proerythroblasts results from differing erythropoietin sensitivities: A mechanism for controlled rates of erythrocyte production. Blood. 1993;82:2340-2352.
6. Koury MJ, Bondurant MC. Erythropoietin retards DNA breakdown and prevents programmed death in erythroid progenitor cells. Science. 1990; 248:378-381.
7. Jacobs-Helber SM, Wickrema A, Birrer MJ, Sawyer ST. AP1 regulation of proliferation and initiation of apoptosis in erythropoietin-dependent erythroid cells. Mol Cell Biol. 1998;18:3699-3707.
8. Silva M, Grillot D, Benito A, Richard C, Nunez G, Fernandez-Luna JL. Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood. 1996;88: 1576-1582.
9. Tilbrook PA, Bittorf T, Busfield SJ, Chappell D, Klinken SP. Disrupted signaling in a mutant J2E cell line that shows enhanced viability, but does not proliferate or differentiate, with erythropoietin. J Biol Chem. 1996;271:3453-3459.
10. Gaffen SL, Lai SY, Longmore GD, Liu KD, Goldsmith MA. Genetic evidence for an additional factor required for erythropoietin-induced signal transduction. Blood. 1999;94:74-86.
11. Zhuang H, Niu Z, He TC, Patel SV, Wojchowski DM. Erythropoietin-dependent inhibition of apoptosis is supported by carboxyl-truncated receptor forms and blocked by dominant-negative forms of JAK2. J Biol Chem. 1995;270:14500-14504.
12. Quelle FW, Wang J, Feng J, et al. Cytokine rescue of p53-dependent apoptosis and cell cycle arrest is mediated by distinct Jak kinase signaling pathways. Genes Dev. 1998;12:1099-1107.
13. Wu H, Liu X, Jaenisch R, Lodish HF. Generation of committed erythroid BFU-E and CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell. 1995;83:59-67.
14. Neubauer H, Cumano A, Muller M, Wu H, Huffstadt U, Pfeffer K. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis. Cell. 1998;93:397-409.
15. Parganas E, Wang D, Stravopodis D, et al. Jak2 is essential for signaling through a variety of cytokine receptors. Cell. 1998;93:385-395.
16. Ihle JN. The Stat family in cytokine signaling. Curr Opin Cell Biol. 2001;13:211-217.
17. L through Stat5 in erythropoietin-dependent progenitor cell lines. J Biol Chem. 1999;274:22165-22169.
18. L induction. Cell. 1999;98:181-191.
19. Teglund S, McKay C, Schuetz E, et al. Stat5a and Stat5b proteins have essential and nonessential, or redundant, roles in cytokine responses. Cell. 1998;93:841-850.
20. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signalling pathway by transcription-dependent and -independent mechanisms. Science. 1999;286:1358-1362.
21. del Peso L, Gonzalez-Garcia M, Page C, Herrera R, Nunez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science. 1997;278:687-689.
22. Datta SR, Dudek H, Tao X, et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 1997;91:231-241.
23. Shimamura A, Ballif BA, Richards SA, Blenis J. Rsk1 mediates a MEK-MAP kinase cell survival signal. Curr Biol. 1999;10:127-135.
24. L. Cell. 1996;87:619-628.
25. Mowat M, Cheng A, Kimura N, Bernstein A, Benchimol S. Rearrangements of the cellular p53 gene in erythroleukemic cells transformed by Friend virus. Nature. 1985;314:633-636.
26. Li JP, D'Andrea AD, Lodish HF, Baltimore D. Activation of cell growth by binding of Friend spleen focus-forming virus gp55 glycoprotein to the erythropoietin receptor. Nature. 1990;343:762-764.
27. Michalovitz D, Halevy O, Oren M. Conditional inhibition of transformation and of cell proliferation by a temperature-sensitive mutant of p53. Cell. 1990;62:671-680.
28. Johnson P, Chung S, Benchimol S. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol Cell Biol. 1993;13:1456-1463.
29. 1 arrest. Mol Cell Biol. 1995;15:6045-6054.
30. Abrahamson JL, Lee JM, Bernstein A. Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. Mol Cell Biol. 1995;15:6953-6960.
31. Canman CE, Gilmer TM, Coutts SB, Kastan MB. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes Dev. 1995;9:600-611.
32. Yonish-Rouach E, Resnitzky D, Lotem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature. 1991;352:345-347.
33. Gollob JA, Murphy EA, Mahajan S, Schnipper CP, Ritz J, Frank DA. Altered interleukin-12 responsiveness in Th1 and Th2 cells is associated with the differential activation of STAT5 and STAT1. Blood. 1998;91:1341-1354.
34. Bossy-Wetzel E, Green DR. Assays for cytochrome c release from mitochondria during apoptosis. Methods Enzymol. 2000;322:235-242.
35. Backway KL, McCulloch EA, Chow S, Hedfey DW. Relationships between the mitochondrial permeability transition and oxidative stress during ara-C toxicity. Cancer Res. 1997;57:2446-2451.
36. Jaster R, Zhu Y, Pless M, Bhattacharya S, Mathey-Prevot B, D'Andrea AD. JAK2 is required for induction of the murine DUB-1 gene. Mol Cell Biol. 1997;17:3364-3372.
37. Yeh WC, Shahinian A, Speiser D, et al. Early lethality, functional NF-kappaB activation, and increased sensitivity to TNF-induced cell death in TRAF2-deficient mice. Immunity. 1997;7:715-725.
38. Miyashita T, Reed JC. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell. 1995;80:293-299.
39. Lin Y, Ma W, Benchimol S. Pidd, a new death-domain-containing protein, is induced by p53 and promotes apoptosis. Nat Genet. 2000;26:122-125.
40. Schuler M, Bossy-Wetzel E, Goldstein JC, Fitzgerald P, Green DR. p53 induces apoptosis by caspase activation through mitochondrial c release. J Biol Chem. 2000;275:7337-7342.
41. Soengas MS, Alarcon RM, Yoshida H, et al. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science. 1999;284:156-159.
42. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. Proc Natl Acad Sci U S A. 1996;93:11848-11852.
43. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. EMBO J. 1999;18:6027-6036.
44. Polyak K, Xia Y, Zweler JL, Kinzler KW, Vogelstein B. A model for p53-induced apoptosis. Nature. 1997;389:300-305.
45. Yamamura Y, Senda H, Kageyama Y, Matsuzaki T, Noda M, Ikawa Y. Erythropoietin and Friend virus gp55 activate different JAK/STAT pathways through the erythropoietin receptor in erythroid cells. Mol Cell Biol. 1998;18:1172-1180.
46. Ilaria RL Jr, Hawley RG, Van Etten RA. Dominant negative mutants implicate STAT5 in myeloid cell proliferation and neutrophil differentiation. Blood. 1999;93:4154-4166.
47. Damen JE, Cutler RL, Jiao H, Yi T, Krystal G. Phosphorylation of tyrosine 503 in the erythropoietin receptor (EpR) is essential for binding the P85 subunit of phosphatidylinositol (PI) 3-kinase and for EpR-associated PI 3-kinase activity. J Biol Chem. 1995;270:23402-23408.
48. Lecoq-Lafon C, Verdier F, Fichelson S, et al. Erythropoietin induces the tyrosine phosphorylation of GAB1 and its association with SHC, SHP2, SHIP, and phosphatidylinositol 3-kinase. Blood. 1999;93:2578-2585.
49. Verdier F, Chretien S, Billat C, Gisselbrecht S, Lacombe C, Mayeux P. Erythropoietin induces the tyrosine phosphorylation of insulin receptor substrate-2. An alternate pathway for erythropoietin-induced phosphatidylinositol 3-kinase activation. J Biol Chem. 1997;272:26173-26178.
50. Scheid MP, Lauener RW, Duronio V. Role of phosphatidylinositol 3′-OH kinase activity in the inhibition of apoptosis in hemopoietic cells: Phosphatidylinositol 3-OH-kinase inhibitors reveal a difference in signaling between interleukin-3 and granulocyte-macrophage colony stimulating factor. Biochem J. 1995;312:159-162.
51. Yao R, Cooper GM. Requirement for phosphatidylinositol-3′ kinase in the prevention of apoptosis by nerve growth factor. Science. 1995;267: 2003-2006.
52. Stambolic V, MacPherson D, Sas D, et al. Regulation of PTEN transcription by p53. Mol Cell. 2001;8:317-325.
53. Chiou SK, Rao L, White E. Bcl-2 blocks p53-dependent apoptosis. Mol Cell Biol. 1994;14:2556-2563.
54. L protects cancer cells from p53-mediated apoptosis. Oncogene. 1995;11:1389-1394.
55. Wang Y, Szekely L, Okan I, Klein G, Wiman KG. Wild-type p53 triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene. 1993;8:3427-3431.
56. Digicaylioglu M, Lipton SA. Erythropoietin-mediated neuroprotection involves cross-talk between Jak2 and NF-κB signalling cascades. Nature. 2001;412:641-647.
57. Rodig SJ, Meraz MA, White JM, et al. Disruption of the Jakl gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. Cell. 1998;93:373-383.
58. Campbell GS, Yu CL, Jove R, Carter-Su C. Constitutive activation of JAK1 in Src-transformed cells. J Biol Chem. 1997;272:2591-2594.
59. Lacronique V. Bouruex A, Monni R, et al. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells. Blood. 2000;95:2076-2083.
60. Ney P, D'Andrea AD. Friend erythroleukemia revisited. Blood. 2000;96:3675-3680.
61. Persons DA, Paulson RE, Loyd MR, et al. Fv2 encodes a truncated form of the Stk receptor tyrosine kinase. Nat Genet. 1999;23:159-165.
62. Nishigaki K, Thompson D, Hanson C, Yugawa T, Ruscetti S. The envelope glycoprotein of friend spleen focus-forming virus covalently interacts with and constitutively activates a truncated form of the receptor tyrosine kinase stk. J Virol. 2001; 75:7893-7903.
63. Bao H, Jacobs-Helber SM, Lawson AE, Penta K, Wickrema K, Sawyer ST. Protein kinase B (c-Akt), phosphatidylinositol 3-kinase, and STAT5 are activated by erythropoietin (EPO) in HCD57 erythroid cells but are constitutively active in an EPO-independent, apoptosis-resistant subclone (HCD57-SRE) cells). Blood. 1999;93:3757-3773.
64. Nishigaki K, Hanson C, Ohashi T, Thompson D, Muszynski K, Ruscetti S. Erythroid cells rendered erythropoietin independent by infection with Friend spleen focus-forming virus show constitutive activation of phosphatidylinositol 3-kinase and Akt kinase: Involvement of insulin receptor substrate-related adapter proteins. J Virol. 2000; 74:3037-3045.
65. Sabbatini P, McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem. 1999;274:24263-24269.